Study Objective:
Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.
Key Requirements:
-
>6 years old - <18 years old
Study Information:
-
Compensation for time and travel up to
-
Transportation can be arranged at no cost to you
-
Study related exams at to cost
Location:
-
TOPAZ Clinical Research 2513 E. Semoran Blvd Apopka, FL 32703